Home » AGEB Journal » Issues » Volume 68 » Fasc.3 - Book review

Volume 68 - 2005 - Fasc.3 - Book review


Rifaximin is a semisynthetic rifamycin first described in1982. It is minimally absorbed by the normal gas- trointestinal tract and which has been recently approved by the FDA in the US for the treatment of traveler's diar- rhea. In Europe, it is likely available only into the italian market. Its antimicrobial activity is broad, mainly against gram-positive bacteria including oxacillin- resistant strains of Staphylococcus aureus, C. difficile and Helicobacter pylori.